The phase 3 trial of the Covid-19 vaccine candidate developed by University of Oxford is underway, and is expected to include 42,000 people when the Oxford-led trial is combined with a phase 3 trial led by its partner, AstraZeneca.
In phase 3, Oxford is enrolling 10,000 people in the UK, and AstraZeneca is enrolling 30,000 in the US. On June 2, the Brazilian government approved the inclusion of volunteers in their country, with 2,000 volunteers to be tested there.
The AstraZeneca portion of the phase 3 trial will begin in August, according to the National Institutes of Health, which will be conducting and funding the trials.
Participants in the phase 3 group will “receive one or two doses” of their Covid-19 vaccine candidate, or another licensed vaccine that will be the control group.